Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Inclusion Criteria: * Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday) * Diagnosis of heterozygous familial hypercholesterolemia * On an approved statin with stable optimized dose for ≥ 4 weeks * Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks) * Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L) * Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) Exclusion Criteria: * Type 1 diabetes, or type 2 diabetes that is or poorly controlled * Uncontrolled hyperthyroidism or hypothyroidism * Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months * Previously received evolocumab or any other investigational therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). * Lipid apheresis within the last 12 weeks prior to screening. * Homozygous familial hypercholesterolemia